Barclays PLC Buys 154,509 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Barclays PLC raised its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 99.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 309,671 shares of the biopharmaceutical company’s stock after purchasing an additional 154,509 shares during the period. Barclays PLC owned 0.16% of Esperion Therapeutics worth $510,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Boomfish Wealth Group LLC raised its holdings in Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares during the last quarter. Summit Financial LLC raised its holdings in shares of Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 6,823 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. BOKF NA bought a new position in Esperion Therapeutics in the 2nd quarter valued at about $26,000. Finally, Xponance Inc. acquired a new position in Esperion Therapeutics during the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.20 on Friday. The firm has a market capitalization of $433.48 million, a PE ratio of -3.44 and a beta of 1.01. The company has a 50 day moving average price of $2.45 and a 200-day moving average price of $2.19. Esperion Therapeutics, Inc. has a 52 week low of $1.58 and a 52 week high of $3.94.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.